Announcements Trials
Browse Landscape

Phase

Phase 1 9Phase NA 3Phase 1/2 3Phase 4 1Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 10Gastrointestinal 10Genitourinary 2Thoracic 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 88Lung Neoplasms 70Small Cell Lung Carcinoma 11Pleural Effusion, Malignant 9Melanoma 7Ovarian Neoplasms 6NSCLC 6Pleural Effusion 5Neoplasms 5Head and Neck Neoplasms 5Stomach Neoplasms 4Mesothelioma 4Lung Diseases 4Carcinoma, Renal Cell 4Carcinoma 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Thoracic Neoplasms 3Pneumothorax 3Pleural Neoplasms 3Pancreatic Neoplasms 3Non-Squamous Non-Small Cell Lung Cancer 3Neoplasm Metastasis 3Liver Neoplasms 3Kidney Neoplasms 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Brain Neoplasms 3Venous Thromboembolism 2Urinary Bladder Neoplasms 2

Interventions

Sunitinib 1Midazolam 1Erlotinib Hydrochloride 1Caffeine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Gastrointestinal Stromal Tumors × Thoracic × Clear all
NCT01402089 2016-02-02

Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients

Cantonal Hospital of St. Gallen

Phase 4 Completed
54 enrolled
GastrointestinalGenitourinarySarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lung Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡